Observational studyJournal of cancer research and clinical oncology2025
Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study.
Observational study in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSystemic anticancer treatments (SACTs) are used in advanced cancer stages to control disease and improve survival. However, their use at the end of life (Eol) can lead to side effects. This study aims to assess the clinical implications of SACTs near the Eol in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
methodsThis is an observational retrospective study conducted at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano. R/M HNSCC patients treated from 2016 to 2024 were included and classified based on the timing of their last SACT relative to death: within 30 days (Cohort 1), and more than 30 days before death (Cohort 2). Cohort 1 was further subdivided into treatments given 15–30 days (1a) or within 14 days (1b) before death. We assessed performance status, survival outcomes, time from last therapy administration to death, fatal acute adverse events, and palliative care referral rates.
resultsOne hundred fifty-five patients were evaluable for the analysis. Patients receiving last anticancer therapy within 30 days of death exhibited worse overall survival compared to those who received their last treatment earlier (HR = 0.69; 95% CI 0.48–1.00; p = 0.047). Fatal acute events occurred in 31% of cases, with respiratory failure and major bleeding as leading causes.
conclusionSACTs within 30 days of death correlates with worse prognosis and more aggressive disease. Major bleeding may be treatment-related when administered within 14 days of death. These findings emphasize the need for careful patient selection and early palliative care integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.